Blinding is a procedure in clinical trials in which specified persons do not know the treatment allocation of individual participants. It is intended to prevent expectations from systematically influencing behavior, care, the recording of events, or the assessment of endpoints. Which roles are blinded must be unambiguously described in the protocol.<\/p>\n
If a participant, an investigator, or an evaluator knows the allocation to investigational product or comparator product, this can lead to avoidable biases. Participants may report symptoms differently or utilize concomitant measures differently. Treating teams may unconsciously influence diagnostics, concomitant therapy, or the decision to discontinue the study. The risk is particularly relevant for subjective or investigator-assessed endpoints.<\/p>\n
Blinding protects not only the endpoint assessment. It also supports the comparability of care and data collection between the study arms. ICH E9 classifies the control of bias among the essential design principles. However, it replaces neither randomization nor an appropriate control group, valid endpoints, or a pre-specified analysis. The appropriate combination of these measures depends on the question, disease, and practical feasibility.<\/p>\n
The protocol specifies for each function whether and until when it remains blinded: participants, study site, sponsor team, endpoint committee, data management, biostatistics, and, if applicable, an independent body can have different access rights. Terms such as single, double, or triple blind are not sufficient because they do not uniformly define which persons actually do not know the allocation.<\/p>\n
The practical implementation can require identical appearance, labelling, and administration of treatments, a randomized allocation, as well as separated roles and data views. Randomization code, access rights, and medicinal product supply must be managed in such a way that an allocation does not unintentionally become apparent. Adverse reaction profiles, laboratory values, or different forms of administration can jeopardize the blind; standardized assessments, objective endpoints, or blinded endpoint committees are then important supplementary measures.<\/p>\n
Prior to study start, processes must be tested against realistic scenarios, for instance in the event of a serious adverse event, a technical fault, or a query regarding the study medication. Trainings must explain which information is sensitive and to which independent body it is passed on. Listings and interim reports, too, must not contain combinations of data for blinded functions that would allow an allocation to be recognized with a high degree of probability. Test runs document whether access control and communication paths function effectively.<\/p>\n
Unblinding is not the blinding itself, but the controlled disclosure of a previously kept secret treatment allocation. An emergency unblinding may only take place according to a pre-specified, medically justified procedure if the knowledge is necessary for the treatment of a person. The occasion, time, authorized role, and possible impact on the analysis are to be documented. An unintentional disclosure is to be evaluated as a deviation and examined for its causes and consequences.<\/p>\n
A double-blind design is a specific manifestation of blinding, not its synonym. It usually describes that participants and the immediately treating or assessing persons do not know the allocation; the exact distribution of roles must nevertheless be stated in the protocol. Blinding can also encompass only one role, such as an independent endpoint committee, or include additional functions. Therefore, unblinding and double-blind design remain independent terms.<\/p>\n
In project practice, blinding concerns the interfaces between study design, randomization, medicinal product supply, safety processes, and data analysis. The protocol, randomization description, and work instructions must define which information is visible in which systems and how emergencies are handled. In audits and inspections, it is decisive whether the planned protection was actually implemented and whether every unblinding is traceably documented.<\/p>\n
Full-service CROs such as Mediconomics support the elaboration of blinding and unblinding processes, the planning of role rights and data flows, as well as the coordination of randomization, monitoring, data management, and biostatistics. They can additionally check the documentation in the protocol and in work instructions for consistency and assess the impact of known unblindings on data review and analysis.<\/p>\n
Is blinding possible in every clinical trial?<\/strong><\/p>\n No. In surgery, significantly different forms of administration, or characteristic effects, it can be limited. In that case, other measures for bias reduction, such as blinded endpoint assessment and objective endpoints, should be planned with justification.<\/p>\n Who is allowed to initiate an emergency unblinding?<\/strong><\/p>\n The procedure must specify in the protocol which authorized roles receive access to the code in the event of medical necessity. The disclosure should be limited to the necessary extent and fully documented.<\/p>\n Is an open-label study methodologically worthless?<\/strong><\/p>\n No. Open-label studies can be appropriate if blinding is not practicable or not necessary. However, their limitations and the intended measures against bias must be transparent in the design and in the interpretation.<\/p>\n Blinding is a procedure in clinical trials in which specified persons do not know the treatment allocation of individual participants. It is intended to prevent expectations from systematically influencing behavior, care, the recording of events, or the assessment of endpoints. Which roles are blinded must be unambiguously described in the protocol. Purpose and influence on […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6598","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6598\/revisions"}],"predecessor-version":[{"id":7446,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6598\/revisions\/7446"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6598"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n